HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors
about
Research Progress of Mechanisms on Intracranial Metastasis of Non-small Cell Lung Cancer after Clinical Benefit from EGFR-TKIPhosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor modelsThe Arf-inducing transcription factor Dmp1 encodes a transcriptional activator of amphiregulin, thrombospondin-1, JunB and Egr1MRI Virtual Biopsy and Treatment of Brain Metastatic Tumors with Targeted Nanobioconjugates: Nanoclinic in the BrainBreast Cancer Brain Metastases: Clonal Evolution in Clinical Context.Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer.Current approaches to the treatment of metastatic brain tumours.Epidermal Growth Factor Receptor Mutational Status and Brain Metastases in Non-Small-Cell Lung CancerProtein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activationHER3 and downstream pathways are involved in colonization of brain metastases from breast cancerThe role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic targetRole of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation.The molecular genomics of metastatic brain tumours.A search for novel cancer/testis antigens in lung cancer identifies VCX/Y genes, expanding the repertoire of potential immunotherapeutic targets.Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines.Anti-tumor efficacy of naked siRNAs for ERBB3 or AKT2 against lung adenocarcinoma cell xenografts.Exon 19 deletion of epidermal growth factor receptor is associated with prolonged survival in brain metastases from non-small-cell lung cancer.Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis.Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers.Molecular aspects of breast cancer metastasis to the brain.Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis.The Influence of Biomarker Mutations and Systemic Treatment on Cerebral Metastases from NSCLC Treated with Radiosurgery.EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome.G-protein coupled receptor family C, group 5, member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small-cell lung cancer.EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patientsA phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling.Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.Gene Expression of the EGF System-a Prognostic Model in Non-Small Cell Lung Cancer Patients Without Activating EGFR Mutations.Sensitive methods for the detection of an insertion in exon 20 of the HER2 gene in the metastasis of non-small cell lung cancer to the central nervous system.Biological resonance for cancer metastasis, a new hypothesis based on comparisons between primary cancers and metastases.Baseline neutrophil-lymphocyte ratio is associated with baseline and subsequent presence of brain metastases in advanced non-small-cell lung cancerXPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR MutationRegulatory mechanisms of betacellulin in CXCL8 production from lung cancer cells.Tracing the origins of metastasis.
P2860
Q26798043-8462C374-1B7E-4906-861E-7F618D8FF3BDQ28473716-60DB471C-9BA6-4E30-85ED-D3A0D0227BE7Q28854364-81201661-AF44-4A61-AC29-F2F87120AC8EQ29248327-1A690C5F-A9D4-43DB-9A22-6D4DB72836F2Q30238959-DA6BFE3C-E7B1-4AB6-9957-C85953086B39Q33434648-BBD661BA-D257-4566-828D-677632009049Q33632386-1BBEFB5E-1E66-43B7-9875-47A8300C4875Q33696559-55976E50-EB9C-4ACE-BB0B-485687436DB8Q33859503-73B21E2F-47F9-4D52-8647-8AC774774D78Q33901255-7EB4ECDB-08A6-4505-93E7-C95AABD48D83Q34173413-DD578812-9EB2-4E65-9FBF-8294FCCB943AQ34349389-5A3BAA6E-86D2-4B13-B27A-A64CFE17079EQ34438536-9F8BFBC9-4F43-4E8D-9480-49DA6FDF4803Q34472367-2D48DEA2-DECD-4B6E-999E-29A74E5B1053Q34499855-881D4F6F-6239-4D1C-B609-C742F5D4F0DDQ35429274-9C122614-D885-434E-BB63-DE772E72D833Q35551911-9BC698E4-1EE5-49B9-8E15-8F92C1F86402Q35563891-EFE727AA-04C2-4093-B0EE-74994DDF8CAFQ35669012-94738525-FDD7-416F-B30D-7F469650F298Q35671281-B1DD854F-D0C2-43E9-927F-65473091F79DQ35791377-EA2863A4-6A38-4FD6-9F38-A0B05F877AB2Q35885064-BA3885CA-94E3-4234-A0F2-3D9B1C581505Q35909895-361A12E5-F10C-4FCE-B0F6-973ED388B91EQ35962441-E289A6BE-13EE-4DDD-8179-C41533BB9671Q36243003-4EB37633-8885-4E69-A1B2-11508839FA24Q36250691-6A9AFED6-3189-4093-8612-AB6BCD936FE0Q36710603-13A84D22-2A3F-4A1B-BC89-959FB0BC7879Q36755508-B26B5DD7-1855-4234-BD21-D5A0DAAF77D7Q36977414-E387B92C-9B9D-4D74-8227-9440AF70E821Q37087347-7E9B814A-3CA3-403D-8A52-B66CE64778EEQ37175654-9537F346-145A-4902-868F-CB03E5C0D4F7Q37190106-DBE1C74E-A847-4996-96D2-4BF04EAF05F3Q37221902-8008C8B9-CDFD-42FC-B41B-823E576C2DD5Q37229404-5A56BEB9-C297-475A-8E50-EDC00CB478FDQ37373790-A3520990-949E-4705-9500-B42C2866D681Q37479765-BE422121-82B7-40FB-8ADD-011B009D6B95Q37510564-ACD3E16D-1EC2-4B62-BE2B-C61A55837E17Q37669061-FEFEB9A5-020B-4F89-8BA0-08BEB3F5018AQ37716531-A15ED7FD-8E96-4BAF-9BFA-E03F15953DA0Q37815132-5E10897B-E1D8-4A3F-BAC0-69E057ADEE8E
P2860
HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
HER family receptor abnormalit ...... d corresponding primary tumors
@ast
HER family receptor abnormalit ...... d corresponding primary tumors
@en
type
label
HER family receptor abnormalit ...... d corresponding primary tumors
@ast
HER family receptor abnormalit ...... d corresponding primary tumors
@en
prefLabel
HER family receptor abnormalit ...... d corresponding primary tumors
@ast
HER family receptor abnormalit ...... d corresponding primary tumors
@en
P2093
P2860
P1476
HER family receptor abnormalit ...... d corresponding primary tumors
@en
P2093
Carmen Behrens
Guosheng Yin
Kenneth D Aldape
Marileila Varella-Garcia
Menghong Sun
Natalie Ozburn
Waun Ki Hong
Ximing Tang
P2860
P304
P356
10.1158/1078-0432.CCR-08-2921
P407
P577
2009-07-21T00:00:00Z